- The Expression of DNA Methyltransferase DNMT3a in Classical and Fibrolamellar Hepatocellular CarcinomaSzparecki, G; Ilczuk, TJournal of Clinical & Experimental Pathology, 2016, 6(3).
- Gunagratinib, a highly selective irreversible FGFR inhibitor, in patients with previously treated locally advanced or metastatic cholangiocarcinoma harboring FGFR pathway alterations: A phase IIa dose-expansion study.Guo, Ye; Yuan, Chunwang; Ding, Weimin; Gao, Yi; Zhu, Xu; Ying, Jieer; Sun, Meili; Zhang, Jingdong; Zhuang, Zhixiang; Huang, Yangqing; Deng, Lichun; Chen, Ping; Bai, Yuxian; Niu, Zuoxing; Li, Wei; Yin, Xiaoyu; Xu, Aibing; Cheng, Yufeng; Li, JinGenitourinary Cancers Symposium, San Francisco, CA, 2023-01-19 To 2023-01-21.被引 2
- Genomic landscape analysis in tumor tissue and circulating tumor DNA of Chinese patients with hepatocellular carcinomaYang, Dinghua; Yu, Sheng; Guo, Baitang; Chen, TingtingAnnual Meeting of the American-Association-for-Cancer-Research (AACR), New Orleans, LA, 2022-04-08 To 2022-04-13.
会议论文
Landscape of FGFR2/3 alterations in hepatobiliary malignancies
8阅读
